Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-α Therapy
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate the safety, tolerability and clinical benefit of
TYSABRI® (natalizumab) in patients with moderately to severely active Crohn's disease.